Effects of prematurity, intrauterine growth status, and early dexamethasone treatment on postnatal bone

Related Experiment Video

Updated: Aug 27, 2026

Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification
07:23

Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification

Published on: December 3, 2016

S Kurl1, K Heinonen, E Länsimies

  • 1Department of Paediatrics, Kuopio University Hospital, PO Box 1777, 70211 Kuopio, Finland. skurl@messi.uku.fi

Archives of Disease in Childhood. Fetal and Neonatal Edition
|August 22, 2000
PubMed

Insights

Preterm infants show reduced bone mineralization compared to term infants. Factors like weight at examination and dexamethasone treatment duration, not intrauterine growth, influence bone health in early infancy.

Area of Science:

  • Neonatal research
  • Pediatric bone health
  • Endocrinology

Background:

  • Prematurity is a significant risk factor for altered infant development.
  • Bone mineralization is crucial for long-term skeletal health.
  • Intrauterine growth status and neonatal factors may impact bone development.

Purpose of the Study:

  • To investigate the influence of intrauterine growth status, neonatal factors, and dexamethasone treatment on bone mineralization in preterm infants.
  • To differentiate the effects of prematurity versus intrauterine growth restriction on bone mineral density.
  • To identify key determinants of bone mineral content in early infancy.

Main Methods:

  • Prospective study comparing preterm small for gestational age (SGA) and appropriate for gestational age (AGA) infants with term controls.
  • Bone mineral content (BMC) and bone mineral density (BMD) measured using dual-energy x-ray absorptiometry (DXA) of the lumbar spine.
  • Measurements standardized for body size to isolate effects on bone mineralization.

Main Results:

  • Preterm infants (both SGA and AGA) exhibited significantly lower BMC and BMD than weight-matched term infants.
  • No significant difference in BMC or BMD was observed between preterm SGA and AGA groups.
  • Stepwise regression identified bone area, dexamethasone treatment duration, weight at examination, and weight gain as significant predictors of BMC.

Conclusions:

  • Postnatal factors, particularly weight at examination and prematurity, significantly impact bone mineralization.
  • Intrauterine growth status does not appear to be a primary determinant of postnatal bone mineralization in this cohort.
  • Dexamethasone treatment duration may also play a role in modulating bone mineral acquisition.
Abstract

More Related Videos

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

Culturing and Measuring Fetal and Newborn Murine Long Bones06:58

Culturing and Measuring Fetal and Newborn Murine Long Bones

Published on: April 26, 2019

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Bone Formation by Intramembranous Ossification01:29

Bone Formation by Intramembranous Ossification

Intramembranous ossification is one of the two processes involved in the development of bones within an embryo. The flat bones of the face, most of the cranial bones, and the clavicles are formed via this process. During intramembranous ossification, the bones develop directly from sheets of undifferentiated mesenchymal connective tissue.
The process begins when mesenchymal cells in the embryonic skeleton gather together and differentiate into osteogenic cells, which then develop into...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...